Affinity purification and diagnostic use of TSH receptor autoantibodies from human serum

被引:25
作者
Morgenthaler, NG
Minich, WB
Willnich, M
Bogusch, T
Hollidt, JM
Weglöhner, W
Lenzner, C
Bergmann, A
机构
[1] BRAHMS AG, Biotechnol Ctr Hennigsdorf Berlin, Res Dept, D-16761 Hennigsdorf, Germany
[2] Bioassays GmbH, Biotechnol Ctr Hennigsdorf Berlin, Res Dept, D-16761 Hennigsdorf, Germany
[3] Invent GmbH, Biotechnol Ctr Hennigsdorf Berlin, Res Dept, D-16761 Hennigsdorf, Germany
[4] In Vivo GmbH, Biotechnol Ctr Hennigsdorf Berlin, Res Dept, D-16761 Hennigsdorf, Germany
关键词
thyroid blocking antibodies; thyroid stimulating antibodies; TSH receptor autoantibodies;
D O I
10.1016/j.mce.2003.09.018
中图分类号
Q2 [细胞生物学];
学科分类号
071009 [细胞生物学]; 090102 [作物遗传育种];
摘要
Purification of TSH receptor autoantibodies (TRAb) from the serum of patients with Graves' disease (GD) might help to elucidate the nature of these disease causing autoantibodies. We describe here for the first time the successful affinity purification of human TRAb. Affinity purification was performed in a four step procedure with human recombinant TSH receptor (TSH-R) expressed in K562 cells. Purification from six different serum pools from patients with GD and two individual sera (one with only thyroid stimulating antibodies (TSAb) one with only thyroid blocking antibodies (TBAb)) resulted in a purity of 39.2 +/- 3.8 IU/mg TRAb or 25.7 +/- 2.1 mug IgG/IU (about 3.5-13.7 mug TRAb/ml serum). The average enrichment based on the respective original serum was 3420-fold (range 1200-10,000). The kDa of the purified TRAb were in the range of 0.7-2.6 x 10(-10) M. All purified TRAb (except from the TBAb serum which showed blocking activity) showed a more than 1000-fold stronger stimulation in the TSAb bioassay based on the IgG content than the original serum, and similar stimulation based on international units (IU/l) TRAb. When labelled purified TRAb were used in a competitive assay as tracer instead of bovine TSH, their binding to the human recombinant TSH-R on tubes was displaced by 99 of 100 GD sera (selected for TBII activity). Correlation to the standard TSH tracer was r = 0.92. Interestingly, the use of TRAb tracer derived from a patient with TSAb and a patient with TBAb gave virtually identical results (r = 0.93) with these patients, suggesting similar if not identical binding sites for both TRAb subtypes. In conclusion, this is the first report on the purification of human TRAb from the serum of patients with GD. The purified TRAb are of low concentration with high affinity, strong TBII and TSAb activity. Further characterisation may allow new insights in TRAb epitope localisation, the pathology of GD and the differences between TSAb and TBAb. Also, their use as tracer in a competitive assay is the first report on a completely homogenous assay with high sensitivity for TSH-R autoantibodies. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:73 / 79
页数:7
相关论文
共 19 条
[1]
A monoclonal thyroid-stimulating antibody [J].
Ando, T ;
Latif, R ;
Pritsker, A ;
Moran, T ;
Nagayama, Y ;
Davies, TF .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (11) :1667-1674
[2]
Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves' patients' sera [J].
Chazenbalk, GD ;
Jaume, JC ;
McLachlan, SM ;
Rapoport, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (30) :18959-18965
[3]
Purification and characterization of a soluble bioactive amino-terminal extracellular domain of the human thyrotropin receptor [J].
Cornelis, S ;
Uttenweiler-Joseph, S ;
Panneels, V ;
Vassart, G ;
Costagliola, S .
BIOCHEMISTRY, 2001, 40 (33) :9860-9869
[4]
Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease [J].
Costagliola, S ;
Morgenthaler, NG ;
Hoermann, R ;
Badenhoop, K ;
Struck, J ;
Freitag, D ;
Poertl, S ;
Weglöhner, W ;
Hollidt, JM ;
Quadbeck, B ;
Dumont, JE ;
Schumm-Draeger, PM ;
Bergmann, A ;
Mann, K ;
Vassart, G ;
Usadel, KH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (01) :90-97
[5]
Generation of a mouse monoclonal TSH receptor antibody with stimulating activity [J].
Costagliola, S ;
Franssen, JDF ;
Bonomi, M ;
Urizar, E ;
Willnich, M ;
Bergmann, A ;
Vassart, G .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 299 (05) :891-896
[6]
Differences in the levels of TSH-binding inhibitor immunoglobulins in goitrous and agoitrous autoimmune thyroiditis after twelve months of L-thyroxine therapy [J].
Khoo, DHC ;
Eng, PHK ;
Ho, SC ;
Fok, ACK .
CLINICAL ENDOCRINOLOGY, 1999, 51 (01) :73-79
[7]
USE OF THYROTROPIN RECEPTOR (TSHR) MUTANTS TO DETECT STIMULATING TSHR ANTIBODIES IN HYPOTHYROID PATIENTS WITH IDIOPATHIC MYXEDEMA, WHO HAVE BLOCKING TSHR ANTIBODIES [J].
KOSUGI, S ;
BAN, T ;
AKAMIZU, T ;
VALENTE, W ;
KOHN, LD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (01) :19-24
[8]
Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor [J].
Morgenthaler, NG ;
Pampel, I ;
Aust, G ;
Seissler, J ;
Scherbaum, WA .
HORMONE AND METABOLIC RESEARCH, 1998, 30 (03) :162-168
[9]
BINDING DOMAINS OF STIMULATORY AND INHIBITORY THYROTROPIN (TSH) RECEPTOR AUTOANTIBODIES DETERMINED WITH CHIMERIC TSH-LUTROPIN CHORIONIC-GONADOTROPIN RECEPTORS [J].
NAGAYAMA, Y ;
WADSWORTH, HL ;
RUSSO, D ;
CHAZENBALK, GD ;
RAPOPORT, B .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (01) :336-340
[10]
STABLE EXPRESSION OF THE HUMAN TSH RECEPTOR IN CHO CELLS AND CHARACTERIZATION OF DIFFERENTIALLY EXPRESSING CLONES [J].
PERRET, J ;
LUDGATE, M ;
LIBERT, F ;
GERARD, C ;
DUMONT, JE ;
VASSART, G ;
PARMENTIER, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 171 (03) :1044-1050